This medicine is indicated for the treatment of acute episodes of ulcerative colitis and for the maintenance treatment of Crohn’s disease.
ROWASA | MESALAZINE
500mg
|
90 tablets
|
Teofarma
$37.74
Outpatient medication - Home delivery
This medication is an intestinal anti-inflammatory agent.
This medication is registered in France under registration number 3400933382315.
This page provides a summary. For contraindications, side effects, or more details, refer to the Patient Information Leaflet.
Please note that the photos are not contractual (for illustration purposes only)
Indications
Therapeutic Action
Pharmacotherapeutic group: Intestinal anti-inflammatory agent.
Mesalazine tablets release the active ingredient slowly which then acts locally to reduce the inflammation and help relieve or stop the pain.
Ulcerative colitis is an inflammatory bowel disease in which the lining of the intestine becomes inflamed and develops many tiny breaks in its surface (ulcers) which may bleed.
Instructions for use
Please refer to the instructions on the prescription established by your medical doctor.
Oral route. To be taken in 3 to 4 doses with meals.
Acute treatment of ulcerative colitis:
- 2 to 4 g per day, i.e., 4 to 8 tablets per day.
- The dosage will be adjusted according to the response to treatment.
- The recommended treatment duration is 4 to 8 weeks.
Maintenance treatment of Crohn’s disease:
- 1.5 to 2 g per day, i.e., 3 to 4 tablets per day.
- The treatment duration is limited to 2 years.
Trust at every step
We provide a clear, reliable process for sourcing and delivering quality-assured medications, of the highest quality standard. They are registered and sold in Europe.
Delivery guarantee
If your medicine couldn't be delivered, we replace it or we pay back your order. Most deliveries happen within 10 days and all orders are trackable.
Addressing long-term health needs
Beyond providing access, we collaborate with local actors to improve availability and affordability of medications locally.